{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lei Y"],"funding":["Self funded research project of the Health Commission of Guangxi Zhuang Autonomous Region","Hunan Science and Technology Youth Talent Support Program","Science and technology innovation Program of Hunan Province"],"pagination":["32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12797744"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(1)"],"pubmed_abstract":["<h4>Background</h4>Chronic kidney disease (CKD) is a significant global health challenge with a multifaceted etiology. Risk stratification and timely intervention are crucial for mitigating CKD progression. Trimethylamine N-oxide (TMAO), a gut microbiota metabolite, has been implicated in CKD pathogenesis. However, the lack of standardized diagnostic assays for TMAO has limited its clinical applicability.<h4>Methods</h4>We conducted a multicenter observational study in Southern China. Plasma TMAO levels were quantified using a newly developed liquid chromatography-mass spectrometry (LC-MS)-based diagnostic kit in a cohort of 272 participants, including healthy controls and CKD patients. We analyzed the correlation between TMAO levels and renal function indicators, evaluated the utility of "],"journal":["BMC nephrology"],"pubmed_title":["Utility of trimethylamine N-oxide (TMAO) as a biomarker for risk stratification in chronic kidney disease: a multicenter observational study."],"pmcid":["PMC12797744"],"funding_grant_id":["2023TJ-N20","Z-A20231168","2023RC3232"],"pubmed_authors":["Jiang J","Xia Z","Li C","Chen L","Zhang H","He M","Deng J","Fei Y","Ouyan D","Zhang W","Qu S","Li X","Lei Y","Fang Q","Ning Y"],"additional_accession":[]},"is_claimable":false,"name":"Utility of trimethylamine N-oxide (TMAO) as a biomarker for risk stratification in chronic kidney disease: a multicenter observational study.","description":"<h4>Background</h4>Chronic kidney disease (CKD) is a significant global health challenge with a multifaceted etiology. Risk stratification and timely intervention are crucial for mitigating CKD progression. Trimethylamine N-oxide (TMAO), a gut microbiota metabolite, has been implicated in CKD pathogenesis. However, the lack of standardized diagnostic assays for TMAO has limited its clinical applicability.<h4>Methods</h4>We conducted a multicenter observational study in Southern China. Plasma TMAO levels were quantified using a newly developed liquid chromatography-mass spectrometry (LC-MS)-based diagnostic kit in a cohort of 272 participants, including healthy controls and CKD patients. We analyzed the correlation between TMAO levels and renal function indicators, evaluated the utility of ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-09T05:38:00.942Z","creation":"2026-06-09T03:07:31.935Z"},"accession":"S-EPMC12797744","cross_references":{"pubmed":["41353350"],"doi":["10.1186/s12882-025-04625-y"]}}